{
  "symbol": "TVTX",
  "company_name": "Travere Therapeutics Inc",
  "ir_website": "https://ir.travere.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Travere Therapeutics to Present at Upcoming Investor Conferences",
          "url": "https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-present-upcoming-investor-conferences-10",
          "content": "[Skip to content](#main)\n\n  * [Contact Us](https://travere.com/contact-us/)\n  * [Careers](https://travere.com/careers/)\n\n\n\n  * [facebook](https://www.facebook.com/TravereRare/)\n  * [instagram](https://www.instagram.com/travererare)\n  * [linkedin](https://www.linkedin.com/company/travererare)\n  * [twitter](https://twitter.com/TravereRare)\n\n\n\n# PRESS **RELEASE**\n\n« [Back](#)\n\n## \n\nTravere Therapeutics to Present at Upcoming Investor Conferences\n\nNov 25, 2024 \n\n[PDF Version](/node/15546/pdf)\n\nSAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:\n\n**7 th Annual Evercore HealthCONx Conference**Tuesday, December 3, 2024, at 10:00 a.m. ET\n\n**Citi 2024 Global Healthcare Conference** Wednesday, December 4, 2024, at 2:30 p.m. ET\n\nLive webcasts of the presentations will be accessible on the Investor page of Travere’s website at [ir.travere.com/events-presentations](http://ir.travere.com/events-presentations), and replays will be available for up to 30 days following each event.\n\n**About Travere Therapeutics**At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit [travere.com](http://travere.com).\n\nContact:\n\nInvestors:888-969-7879IR@travere.com | Media:888-969-7879mediarelations@travere.com  \n---|---  \n  \n![](https://ml.globenewswire.com/media/ZmIwZTRjYzMtYWUyZi00MDA3LWE0YWMtOTFmMWVlZTA5NmNmLTEwMTU4NDQ=/tiny/Travere-Therapeutics-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/e7252f5a-bd9e-4e33-9eb0-153976c06a3f)\n\nSource: Travere Therapeutics, Inc.\n\n[ Print Page ]()\n\n[ Email Alerts ](/shareholder-services/email-alerts)\n\n[ Download Library ](/download-library)\n\n[ RSS Feeds ](/rss-feeds)\n\n[ Share ]()\n\n[ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-present-upcoming-investor-conferences-10 \"Facebook\") [ ](https://twitter.com/intent/tweet?text=&url=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-present-upcoming-investor-conferences-10 \"Twitter\") [ ](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-present-upcoming-investor-conferences-10&title=Investor+Relations \"LinkedIn\")\n\n[ Search ](/search)\n"
        },
        {
          "title": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
          "url": "https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-reports-inducement-grants-under-nasdaq-29",
          "content": "[Skip to content](#main)\n\n  * [Contact Us](https://travere.com/contact-us/)\n  * [Careers](https://travere.com/careers/)\n\n\n\n  * [facebook](https://www.facebook.com/TravereRare/)\n  * [instagram](https://www.instagram.com/travererare)\n  * [linkedin](https://www.linkedin.com/company/travererare)\n  * [twitter](https://twitter.com/TravereRare)\n\n\n\n# PRESS **RELEASE**\n\n« [Back](#)\n\n## \n\nTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\n\nNov 13, 2024 \n\n[PDF Version](/node/15516/pdf)\n\nSAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable vesting dates.\n\n**About Travere Therapeutics**\n\nAt Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit [travere.com](http://travere.com).\n\nContact Info\n\nMedia:888-969-7879 mediarelations@travere.com| Investors:888-969-7879 IR@travere.com  \n---|---  \n  \n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MDc2NiM2NTczNTU5IzIwMDQyNzE=)\n\n![](https://ml.globenewswire.com/media/N2Y0MTU3ZjUtYjY1Ny00NmIzLTlkY2YtMjU1NGVlNDQzM2VjLTEwMTU4NDQ=/tiny/Travere-Therapeutics-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/e7252f5a-bd9e-4e33-9eb0-153976c06a3f)\n\nSource: Travere Therapeutics, Inc.\n\n[ Print Page ]()\n\n[ Email Alerts ](/shareholder-services/email-alerts)\n\n[ Download Library ](/download-library)\n\n[ RSS Feeds ](/rss-feeds)\n\n[ Share ]()\n\n[ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-reports-inducement-grants-under-nasdaq-29 \"Facebook\") [ ](https://twitter.com/intent/tweet?text=&url=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-reports-inducement-grants-under-nasdaq-29 \"Twitter\") [ ](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-reports-inducement-grants-under-nasdaq-29&title=Investor+Relations \"LinkedIn\")\n\n[ Search ](/search)\n\nThis website uses cookies for optimal site functionality. To understand more about the cookies we use, or to change your cookie preferences, click on \"Cookie Settings.\" For more information, please see our[Privacy Policies.](https://travere.com/privacy/)\n\nDecline All  Accept All Cookies\n\nCookie Settings\n\n![Company Logo](https://cdn.cookielaw.org/logos/0a637489-d841-4c26-9c63-045070c77165/1a7e4b27-ccb1-4583-ab46-834ed6801f18/b376ce78-cd4c-4ae0-8d1a-1032a412b9ed/Travere-Tx-Inline-fullcolor.png)\n\n## Privacy Preference Center\n\nYour Opt Out Preference Signal is Honored\n\n  * ### Your Privacy Choices\n\n  * ### Strictly Necessary Cookies\n\n  * ### Performance Cookies\n\n  * ### Functional Cookies\n\n  * ### Targeting Cookies\n\n\n\n\n#### Your Privacy Choices\n\nWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Under some data protection laws, when a cookie is placed by a third-party for the purposes of advertising or marketing to you, this may be considered a sale or sharing of your personal information. Because we respect your right to privacy, you may choose to opt-out of such sale or sharing of your personal information by clicking on the “Decline All” button below. You may also choose to opt-out of certain categories of cookies by clicking through the different category headings of cookies and changing your selection. Please note, however, that blocking some types of cookies may impact your experience of the site and the services we are able to offer. For more information, please see our [ Privacy Policy](https://travere.com/privacy/corporate-privacy-policy/)and our [ Cookie Policy. ](https://travere.com/privacy/website-cookies-policy/)\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\nCookies Details‎\n\n#### Performance Cookies\n\nPerformance Cookies Active\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\nCookies Details‎\n\n#### Functional Cookies\n\nFunctional Cookies Active\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\nCookies Details‎\n\n#### Targeting Cookies\n\nTargeting Cookies Active\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nCookies Details‎\n\nBack Button\n\n### Cookie List\n\nFilter Button\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConfirm My Choices\n\nDecline All Allow All\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        },
        {
          "title": "Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares",
          "url": "https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-completion-public-offering-1",
          "content": "[Skip to content](#main)\n\n  * [Contact Us](https://travere.com/contact-us/)\n  * [Careers](https://travere.com/careers/)\n\n\n\n  * [facebook](https://www.facebook.com/TravereRare/)\n  * [instagram](https://www.instagram.com/travererare)\n  * [linkedin](https://www.linkedin.com/company/travererare)\n  * [twitter](https://twitter.com/TravereRare)\n\n\n\n# PRESS **RELEASE**\n\n« [Back](#)\n\n## \n\nTravere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares\n\nNov 12, 2024 \n\n[PDF Version](/node/15506/pdf)\n\nSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 8,984,375 shares of its common stock at a price to the public of $16.00 per share, including 1,171,875 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offering were approximately $143.8 million, before deducting the underwriting discounts and commissions and offering expenses.\n\nJefferies and Leerink Partners acted as the joint book-running managers for the offering and Wedbush PacGrow acted as co-manager.\n\nThe shares of common stock described above were offered by Travere pursuant to a shelf registration statement filed by Travere with the Securities and Exchange Commission (SEC) that became automatically effective on August 1, 2024. A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website located at <http://www.sec.gov>. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [Prospectus_Department@Jefferies.com](https://www.globenewswire.com/Tracker?data=jMrzQVZfZIhBk94QvfwI1aW8R0qhdNTIsGcKJj6CtSykJUh9o5GkGEdqMjtq2qC_hjoyOEnrzJz-8WU0RFGrE_kRH0xNqH8klqCI1PT2mRPIHXZYJ2ZHodOufs84QK4fieMssWiCNCpDABTHgf5xpA==); or from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at [syndicate@leerink.com](https://www.globenewswire.com/Tracker?data=pwHP4oRJBpXWa_NHjgqfcWWzbNcjrT5dZO5D-dOlwHWV78fuAM_N7p1r_5ixVxwXt6IzWU35pzTq4vWrwp9UhVl9VkFafRyX-O2eSUW19tE=).\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.\n\n**About Travere Therapeutics**\n\nAt Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.\n\nContact:888-969-7879[IR@travere.com](https://www.globenewswire.com/Tracker?data=6SFWuawS0P8khLUN_Zl2eZMHPKH4XItXEW-RBYmAIFg8KberiOf8ejddCC84F7jCG5amKEnyXaFKnmPMLT2cLg==)\n\n![](https://ml.globenewswire.com/media/NTk0ZDQzMmMtODZiZS00OWY2LWIyMGQtNGJiZWRiNmI1MWI1LTEwMTU4NDQ=/tiny/Travere-Therapeutics-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/e7252f5a-bd9e-4e33-9eb0-153976c06a3f)\n\nSource: Travere Therapeutics, Inc.\n\n[ Print Page ]()\n\n[ Email Alerts ](/shareholder-services/email-alerts)\n\n[ Download Library ](/download-library)\n\n[ RSS Feeds ](/rss-feeds)\n\n[ Share ]()\n\n[ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-announces-completion-public-offering-1 \"Facebook\") [ ](https://twitter.com/intent/tweet?text=&url=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-announces-completion-public-offering-1 \"Twitter\") [ ](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fir.travere.com%2Fnews-releases%2Fnews-release-details%2Ftravere-therapeutics-announces-completion-public-offering-1&title=Investor+Relations \"LinkedIn\")\n\n[ Search ](/search)\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Citi 2024 Global Healthcare Conference",
          "url": "https://ir.travere.com/events/event-details/citi-2024-global-healthcare-conference",
          "content": "[Skip to content](#main)\n\n  * [Contact Us](https://travere.com/contact-us/)\n  * [Careers](https://travere.com/careers/)\n\n\n\n  * [facebook](https://www.facebook.com/TravereRare/)\n  * [instagram](https://www.instagram.com/travererare)\n  * [linkedin](https://www.linkedin.com/company/travererare)\n  * [twitter](https://twitter.com/TravereRare)\n\n\n\n# EVENT **DETAILS**\n\n  * [Home](https://travere.com/) ▶\n  * [Investors & Media](/) ▶\n  * Citi 2024 Global Healthcare Conference \n\n\n\n« [Back](#)\n\n## Citi 2024 Global Healthcare Conference\n\nDec 04, 2024 at 2:30 p.m. ET \n\n[Add to Outlook](/node/15541/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Travere Therapeutics, Inc. - Citi 2024 Global Healthcare Conference&dates=20241204T193000Z/20241204T193000Z&details=Event Details: http://ir.travere.com/events/event-details/citi-2024-global-healthcare-conference%0A%0AWebcast: https://kvgo.com/2024-global-healthcare-conference/travere-therapeutics-december&location=&trp=false&sprop=&sprop=name:)\n\n[Listen to webcast](https://kvgo.com/2024-global-healthcare-conference/travere-therapeutics-december)\n\n[ Print Page ]()\n\n[ Email Alerts ](/shareholder-services/email-alerts)\n\n[ Download Library ](/download-library)\n\n[ RSS Feeds ](/rss-feeds)\n\n[ Share ]()\n\n[ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fir.travere.com%2Fevents%2Fevent-details%2Fciti-2024-global-healthcare-conference \"Facebook\") [ ](https://twitter.com/intent/tweet?text=&url=https%3A%2F%2Fir.travere.com%2Fevents%2Fevent-details%2Fciti-2024-global-healthcare-conference \"Twitter\") [ ](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fir.travere.com%2Fevents%2Fevent-details%2Fciti-2024-global-healthcare-conference&title=Investor+Relations \"LinkedIn\")\n\n[ Search ](/search)\n\nThis website uses cookies for optimal site functionality. To understand more about the cookies we use, or to change your cookie preferences, click on \"Cookie Settings.\" For more information, please see our[Privacy Policies.](https://travere.com/privacy/)\n\nDecline All  Accept All Cookies\n\nCookie Settings\n\n![Company Logo](https://cdn.cookielaw.org/logos/0a637489-d841-4c26-9c63-045070c77165/1a7e4b27-ccb1-4583-ab46-834ed6801f18/b376ce78-cd4c-4ae0-8d1a-1032a412b9ed/Travere-Tx-Inline-fullcolor.png)\n\n## Privacy Preference Center\n\nYour Opt Out Preference Signal is Honored\n\n  * ### Your Privacy Choices\n\n  * ### Strictly Necessary Cookies\n\n  * ### Performance Cookies\n\n  * ### Functional Cookies\n\n  * ### Targeting Cookies\n\n\n\n\n#### Your Privacy Choices\n\nWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Under some data protection laws, when a cookie is placed by a third-party for the purposes of advertising or marketing to you, this may be considered a sale or sharing of your personal information. Because we respect your right to privacy, you may choose to opt-out of such sale or sharing of your personal information by clicking on the “Decline All” button below. You may also choose to opt-out of certain categories of cookies by clicking through the different category headings of cookies and changing your selection. Please note, however, that blocking some types of cookies may impact your experience of the site and the services we are able to offer. For more information, please see our [ Privacy Policy](https://travere.com/privacy/corporate-privacy-policy/)and our [ Cookie Policy. ](https://travere.com/privacy/website-cookies-policy/)\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\nCookies Details‎\n\n#### Performance Cookies\n\nPerformance Cookies Active\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\nCookies Details‎\n\n#### Functional Cookies\n\nFunctional Cookies Active\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\nCookies Details‎\n\n#### Targeting Cookies\n\nTargeting Cookies Active\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nCookies Details‎\n\nBack Button\n\n### Cookie List\n\nFilter Button\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConfirm My Choices\n\nDecline All Allow All\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        }
      ]
    }
  ]
}